Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock

Daniel Karlin, Chief Medical Officer and Director at Definium Therapeutics Inc., sold 10,853 shares of the company's stock on September 25, 2026, for a total of $396,894. The sales were made in increments, with prices ranging from $36.24 to $36.98 per share, and were executed under a pre-established trading plan to meet tax obligations associated with the vesting of restricted stock units.

The current share price of DFTX is $38.21, marking a 224% increase over the past year. Despite this, the stock may be considered slightly overvalued, according to InvestingPro. Following the sale, Karlin still owns 792,846 shares of Definium Therapeutics. Meanwhile, the company reported positive Phase 3 trial results for its DT120 oral tablet intended to treat generalized anxiety disorder, with the 100µg dose showing significant improvement over control.

This success has led several financial firms to raise their price targets for Definium Therapeutics, with Canaccord Genuity, Stifel, and H.C. Wainwright all maintaining a Buy rating. The positive outlook for Definium Therapeutics is further supported by a recent FDA hearing that indicated a supportive regulatory environment for the psychedelics sector, which could potentially benefit companies like Definium Therapeutics.